Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retapamulin for Mupirocin-Resistant MRSA Decolonization
NCT03304873Phase 3
Key facts
- Status
- Completed
- Start
- Dec 2017
- Primary completion
- Feb 2019
- Countries
- 1
- Sponsor
- NYU Langone Health
- Modality
- Small Molecules
- Drugs
- retapamulin
- Conditions
- Staphylococcus aureus colonization
01
Overview
Phase 3, randomised, double-blind trial in Staphylococcus aureus colonization comparing Retapamulin with Placebo (2 arms). Primary endpoint: Number of Participants With MRSA Carriage at 1 week. Started Dec 2017; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Retapamulin
Retapamulin ointment applied twice daily for 5 days
Placebo
White petrolatum ointment applied twice daily for 5 days
03
Who it enrols
Pediatric patients (9 months to 17 years) with confirmed mupirocin-resistant MRSA colonization residing in specific Orthodox Jewish neighborhoods.
04
Endpoints
Primary
Number of Participants With MRSA Carriage
Beyond the preview
Go deeper on NCT03304873.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03304873.